$CAPR Capricor Therapeutics is releasing a regulatory update tied to the Deramiocel BLA for Duchenne Muscular Dystrophy, signaling ongoing FDA review with a late-November communication. The disclosure confirms regulatory momentum and potential upside depending on the agency’s assessment, creating a near-term catalyst as the FDA decision window progresses. Given the lack of new data points beyond regulatory status, the move hinges on favorable regulatory interpretation and timing of potential milestones related to the BLA.
#Biotech #FDA
443
$MSTR After-hours action centers on a finalized legal milestone: the court granted final approval to the Roundup class settlement, resolving a major mass tort exposure. The approval closes the anticipated litigation pathway and reduces long-tail regulatory/legal uncertainty around the matter. The decision is a concrete, non-recurring event that completes a known legal process, potentially easing overhang and supporting sentiment that legal liabilities are nearing closure. The timing aligns with the post-close window, underscoring a clear, material regulatory catalyst that could influence near-term risk pricing.
#Crypto
1
58
$PAYO OCC conditional approval to form the Stablecoin National Trust Bank marks a clear regulatory milestone that enables Payoneer to establish a stablecoin-focused national bank. This progress supports the company’s strategy to expand into digital currency infrastructure and adjacent payment ecosystems, potentially unlocking new revenue streams from custody, settlement, and digital-asset-enabled services as the platform scales in the after-hours window.
41
$KYMR Kymera Therapeutics is awaiting KT-621 (BROADEN2) Phase 2b results in Atopic Dermatitis, with an upcoming November 23, 2026 release. The event carries regulatory materiality and is positioned to influence potential approvals or guidance if outcomes are favorable, signaling upside for near-term momentum as data readouts trigger re-rating around efficacy signals and safety in this indication.
#Biotech #Guidance
274
$BLNE Beeline Holdings Inc. is advancing its go-private merger with TYTL Corp, with a scheduled joint stakeholder update call to address the merger agreement. The ongoing merger progress and the upcoming stakeholder discussion indicate near-term momentum around the transaction, suggesting potential upside for investors as the integration and go-private process moves forward.
72
$NVO Novo Nordisk announces FDA approval of Sogroya for pediatric Turner Syndrome, marking the first-and-only once-weekly, long-acting growth hormone option for TS in children. The approval could enhance adherence and simplify treatment in a niche but high-need growth disorder segment, potentially expanding the company’s growth-hormone franchise beyond existing indications and driving incremental patient access in pediatric markets.
#Biotech #FDA
119
$PMVP PMV Pharmaceuticals reports promising updated data from the PYNNACLE Phase 2 pivotal trial of rezatapopt monotherapy in TP53 Y220C-mutated advanced solid tumors, signaling potential regulatory momentum for rezatapopt. The data release strengthens the case for near-term FDA engagement and could accelerate discussions around next-step pivotal planning, as investors interpret the results as a meaningful proof point in a difficult-to-treat subset.
#Biotech #FDA
$KEP KEPCO plans an extraordinary general meeting to approve amendments to its Articles of Incorporation, including enabling electronic participation for shareholder resolutions. The changes are slated to become effective at the start of 2027, contingent on ministerial approval. The event focuses on governance and remote participation capabilities, with signatures and proceedings confirming the proposed amendments. The catalyst centers on corporate-structure flexibility and shareholder-accessibility improvements rather to near-term earnings or guidance.
#Earnings #Guidance
50
$SAGT Sagtec Global Limited disclosed that CEO Ng Chen Lok acquired 260,000 additional Class A ordinary shares at US$1.03 each, for an aggregate US$267,800, increasing Class A beneficial ownership from 8,752,600 to 9,012,600. The CEO also holds 2,000,000 Class B shares (100% of Class B outstanding). Under the dual-class structure, this purchase strengthens the CEO’s voting influence while signaling ongoing personal investment in Sagtec’s long-term growth strategy.
93
$POAS Phaos Technology Holdings (Cayman) Limited issued a correction to its prior September 18, 2026 disclosure about shareholdings, with the update published on November 20. The filing clarification centers on timing related to the corrected ownership disclosures. No new financial metrics or guidance are provided in the correction, and there is no indication of dilution effects from this update. The event is categorized as regulatory/legal with a neutral directional implication for the stock in the near term.
#Biotech #Guidance
92
$APRE Aprea Therapeutics announced interim results from the ongoing first-in-human Phase 1 study of the WEE1 inhibitor APR-1051 (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona. The presentation timing, coupled with ongoing dose-escalation data in patients with advanced solid tumors, is designed to draw investor attention to emerging biological activity and tolerability signals as the program advances through early clinical milestones. The conference-driven disclosures focus on interim safety and preliminary activity, potentially setting up upside visibility into forthcoming readouts.
#Biotech
84
$IBN CRISIL reaffirmed ICICI Bank Limited's credit ratings for its facilities/instruments, communicated via a CRISIL press release and disclosed in ICICI Bank's Form 6-K. The reaffirmation is linked to a rating action dated November 18, 2026 and appears in materials filed around November 19, 2026, suggesting a regulatory acknowledgment rather than new earnings or guidance. No immediate financial metrics or forward-looking projections are provided in the cited materials.
#Earnings #Guidance
66
$MOG.A Moog Inc. reported record fiscal 2026 results and issued guidance for another strong year, underscoring higher earnings and improved cash generation. Net earnings for the year were $419,921 thousand, with diluted earnings per share of $13.11, while operating cash flow reached $443,037 thousand and capital expenditures were $136 million. The company highlighted free cash flow improvement driven by higher earnings and better working capital efficiency (lower net working capital as a percentage of sales), signaling solid fundamentals supporting the optimistic outlook for fiscal 2027.
#Earnings #Guidance
45
$NVNO NVNO presents three-year surgical venous valve data showing a sustained 5.8-point improvement in the rVCSS score through 36 months, underscoring durable clinical benefit. The release also highlights the next-generation enVVe transcatheter system and references a prospective multicenter pivotal study (TAVVE) with FDA involvement, anchoring upside potential to an expanded clinical platform and regulatory-engaged development pathway. The VEITH Symposium presentation framing reinforces ongoing momentum around enVVe and potential near-term near-term regulatory-close activity around the program.
#FDA
36
$SVRA Regulatory/Legal catalyst centers on FDA inaction by the PDUFA deadline for Molgramostim BLA in Autoimmune PAP. While the official outcome is a no-action stance by that milestone, the lack of immediate action can de-risk near-term disappointment and set up potential upside if a subsequent plan (resubmission, additional data, or advisory committee rationale) emerges. The signal supports a continuation of the Molgramostim program and keeps the door open for future regulatory pathways without creating near-term dilution risk.
#Biotech #FDA
1
402
$VWAV VisionWave Holdings, Inc. announced the acquisition of Critical Minerals Intelligence Platform, expanding VisionWave's defense supply-chain intelligence capabilities and accelerating near-term commercialization opportunities. The public announcement ties the deal to strategic partnerships and provides near-term visibility into integration and monetization prospects. There are no explicit dilution indicators in the extracted facts. The catalyst reflects an M&A move rather than a standalone earnings or guidance release, with emphasis on expanded capabilities rather than guaranteed revenue.
#Earnings #Guidance
1
195
$KRMN Karman Space & Defense secured a Navy contract worth $31 million for Virginia-class submarine propulsor tailcones, delivering near-term revenue visibility tied to a government program. The award confirms commercial traction with a strong defense anchor and supports upside momentum for the company as production scales to meet defense obligations. The $31 million size provides a concrete, measurable uplift in funded activity, aligning with a favorable government procurement cadence and potential follow-on opportunities related to the program.
79
$BLTE Belite Bio announces an extension of the FDA review timeline for Tinlarebant NDA, announced Nov 20, 2026. The extension is tied to the FDA review process rather than Belite’s operational metrics, signaling a regulatory delay rather than a milestone achievement. This negative regulatory development could pressure near-term upside catalysts until the agency confirms the revised timeline and potential next steps for Tinlarebant’s submission.
#Biotech #FDA
118
$ANVS Annovis Bio reports FDA agreement on the Integrated Summary of Safety Plan (ISS) for buntanetap, combining Alzheimer’s and Parkinson’s safety data ahead of the NDA. This regulatory milestone de-risks the path and signals readiness for formal NDA submission, as safety integration across indications advances toward a unified filing phase.
#Biotech #FDA
44
$YFOR YYForce secures a two-year security contract in Singapore valued at SGD 831,120, signaling follow-on revenue potential from a confirmed commercial engagement. The deal expands recurring services in a key APAC market, with cashflow expectation running across 24 months and a measurable, non-trivial contract value that compounds if performance-based milestones or renewals occur.
178
